Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Telix Pharmaceuticals and Atlab Pharma Conclude Therapeutic Product Development Agreement for Prostate Cancer

ASX, News,

Telix is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma SAS…

Read more

Telix Pharmaceuticals Acquires Glioblastoma Program from Therapeia

ASX, News,

Telix is pleased to announce a product development partnership with Therapeia GmbH & Co KG…

Read more

Wilex Signs Antibody License Agreement With Telix Pharmaceuticals Limited

News,

Telix is delighted to have established this licensing agreement with Wilex for an important product with the potential to significantly impact cancer…

Read more
1 … 46 47 48

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings